Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note INTASYL self-delivering siRNA compound. Evaluated via intratumoral administration in a U.S. multi-center Phase 1b dose-escalating trial in cSCC.
PH-894
Preclinical · ActiveModality: siRNA
Target BRD4
Indications
Cancer(Preclinical)
Status note INTASYL compound targeting BRD4. Preclinical; the Company is weighing whether/when to fund additional pipeline programs including PH-894.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.